Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-10-11 Fund Information / Fact…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年9月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a revenue summary report from a listed company, providing monthly and cumulative net operating revenue figures with year-over-year comparisons. It includes notes on accounting standards (IFRS) and reporting practices but does not contain comprehensive financial statements or detailed analysis. The document length is short (777 characters) and resembles a brief financial data disclosure rather than a full financial report. It is not an announcement of a report publication but a direct data disclosure. Given the nature of the content as a brief summary of key financial figures, it fits best into the category of Fund Information / Factsheet (FS), which covers brief summaries of key company financials and market info.
2024-10-11 Chinese
113年10月內部人持股轉讓(事前)
Director's Dealing Classification · 100% confidence The document is a report of a personal share transaction by a company director or executive, detailing the planned transfer of shares by an insider (manager本人) including dates, share quantities, and trust details. It does not contain financial statements, earnings data, or regulatory announcements beyond insider dealing. This matches the definition of Director's Dealing (DIRS). The document length and content confirm it is not a report publication or regulatory filing but a direct insider transaction report.
2024-10-08 Chinese
113年09月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, general managers, and other executives. It lists their share types, holdings at appointment, changes in holdings during the month, and current holdings. The content focuses on insider share transactions and holdings disclosures. There is no indication of financial statements, earnings data, meeting materials, or legal proceedings. The document is a report of personal share transactions and holdings by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is substantial and contains actual data, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is DIRS with high confidence.
2024-10-08 Chinese
113年09月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, independent directors, general managers, and other executives. It shows the number of shares held, pledged shares, and related percentages. The content focuses on insider shareholdings and their changes, which is typical of a Director's Dealing or insider share transaction report. There is no indication of financial statements, earnings data, or meeting materials. The document length is 3799 characters, which is relatively short but contains detailed insider shareholding data. Therefore, the document is best classified as a Director's Dealing report.
2024-10-08 Chinese
113年9月變更登記
Regulatory Filings Classification · 90% confidence The document is a brief disclosure from a listed company (美時) providing details about its capital stock, including authorized capital, paid-in capital, and changes in capital structure. It includes specific numeric data about shares and capital amounts but does not contain financial statements, management discussion, or detailed financial performance data. The document length is only 846 characters, indicating it is a short announcement rather than a full report. There is no indication of an annual or interim report, audit report, or earnings release. The content focuses on capital stock information, but it is not announcing a new share issue or capital change event explicitly; rather, it is a static disclosure of capital stock status. Given the nature and length, this fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2024-09-27 Chinese
公告本公司註銷收回之限制員工權利新股 辦理減資變更登記完成
Capital/Financing Update Classification · 95% confidence The document is a short announcement (1000 characters) from a listed company (1795 美時) regarding the completion of capital reduction registration following regulatory approval. It details changes in paid-in capital, shares outstanding, and net asset value per share, but does not contain comprehensive financial statements or detailed financial analysis. The document is an official notification of a capital structure change (capital reduction) rather than a full financial report. It is not a full Annual Report, Interim Report, or Earnings Release. Given the content and length, it fits best under Capital/Financing Update (CAP).
2024-09-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.